Abstract: A flavoring sheet with improved physical properties, a smoking article including the same, and methods of producing the flavoring sheet and the smoking article are provided. The flavoring sheet according to some embodiments of the present disclosure may include a hydrocolloid material configured to form a sheet, a flavoring, and a plasticizer. The plasticizer can improve physical properties of the flavoring sheet and thus enhance workability of a process of cutting the flavoring sheet.

Abstract: A positive electrode active material, a method of preparing the same, and a positive electrode and lithium secondary battery including the same are disclosed herein. In some embodiments, a positive electrode active material includes a lithium transition metal oxide which contains 60 mol % or more of nickel based on a total number of moles of transition metals excluding lithium in the lithium transition metal oxide, wherein the oxide is in a form of a secondary particle which is an aggregate of primary particles, wherein the lithium transition metal oxide satisfies Equation 1: 1 ? x y ? 20 Wherein x is a minimum area of a rectangle including all pores having an area greater than 0.002 ?m2 among closed pores distributed in the secondary particle, and y is a total sum of areas of the pores having an area greater than 0.002 ?m2 among the closed pores distributed in the secondary particle.

Abstract: The present invention relates to an artificially manipulated unsaturated fatty acid biosynthesis-associated factor and use thereof to increase the content of a specific unsaturated fatty acid of a plant body. More particularly, the present invention relates to a system capable of artificially controlling unsaturated fatty acid biosynthesis and a plant body produced thereby, which include an artificially manipulated unsaturated fatty acid biosynthesis-associated factor to control unsaturated fatty acid biosynthesis and a composition capable of artificially manipulating the factor. In a specific aspect, the present invention relates to artificially manipulated unsaturated fatty acid biosynthesis-associated factors such as FAD2, FAD3, FAD6, FAD7 and FAD8 and/or an unsaturated fatty acid biosynthesis controlling system by an expression product thereof.

Abstract: A smoking article according to an example embodiment include a medium receiver filled with a plurality of medium granules, a humectant receiver located on one side of the medium receiver and configured to generate an aerosol, and a filter located on the other side of the medium receiver. The plurality of medium granules are 0.25 mm or more in diameter.

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: The present invention relates to an artificially manipulated unsaturated fatty acid biosynthesis-associated factor and use thereof to increase the content of a specific unsaturated fatty acid of a plant body. More particularly, the present invention relates to a system capable of artificially controlling unsaturated fatty acid biosynthesis and a plant body produced thereby, which include an artificially manipulated unsaturated fatty acid biosynthesis-associated factor to control unsaturated fatty acid biosynthesis and a composition capable of artificially manipulating the factor. In a specific aspect, the present invention relates to artificially manipulated unsaturated fatty acid biosynthesis-associated factors such as FAD2, FAD3, FADE, FAD7 and FAD8 and/or an unsaturated fatty acid biosynthesis controlling system by an expression product thereof.

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: The present invention relates to an artificially manipulated unsaturated fatty acid biosynthesis-associated factor and use thereof to increase the content of a specific unsaturated fatty acid of a plant body. More particularly, the present invention relates to a system capable of artificially controlling unsaturated fatty acid biosynthesis and a plant body produced thereby, which include an artificially manipulated unsaturated fatty acid biosynthesis-associated factor to control unsaturated fatty acid biosynthesis and a composition capable of artificially manipulating the factor. In a specific aspect, the present invention relates to artificially manipulated unsaturated fatty acid biosynthesis-associated factors such as FAD2, FAD3, FADE, FAD7 and FAD8 and/or an unsaturated fatty acid biosynthesis controlling system by an expression product thereof.

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: The present disclosure discloses a catalyst for directly producing a lactide which is a cyclic ester used as a monomer for polylactides, and a method for directly producing a lactide using the catalyst, the method including the transesterification reaction between two molecules of an ester of lactic acid or a mixture containing the ester of lactic acid with a small amount of lactic acid and oligomer of lactic acid under an inert environment in the presence of a titanium-based catalyst or a catalyst mixture containing the titanium-based catalyst so as to produce lactide while simultaneously removing an alcohol (ROH) generated as a by-product.

Abstract: The present disclosure discloses a catalyst for directly producing a lactide which is a cyclic ester used as a monomer for polylactides, and a method for directly producing a lactide using the catalyst, the method including the transesterification reaction between two molecules of an ester of lactic acid or a mixture containing the ester of lactic acid with a small amount of lactic acid and oligomer of lactic acid under an inert environment in the presence of a titanium-based catalyst or a catalyst mixture containing the titanium-based catalyst so as to produce lactide while simultaneously removing an alcohol (ROH) generated as a by-product.

Abstract: The present invention relates to a sustained-release formulation of an animal growth hormone and a process for preparation thereof, comprising a step to produce solid pellets by mixing an animal growth hormone and an excipient in accordance with a direct tabletting method and a step to coat the pellets with a film comprising a biodegradable polymer and a poloxamer. The thus obtained formulation has small initial drug release, and shows a continuous and uniform effect when administered. Further, the formulation of the present invention may be produced economically in a large scale.